Literature DB >> 22414903

Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.

Kevin M Watt, Michael Cohen-Wolkowiez, Robert M Ward, Daniel K Benjamin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22414903      PMCID： PMC3356443          DOI： 10.1097/INF.0b013e31824f8426

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


× No keyword cloud information.
  24 in total

1.  Outcomes following candiduria in extremely low birth weight infants.

Authors:  James L Wynn; Sylvia Tan; Marie G Gantz; Abhik Das; Ronald N Goldberg; Ira Adams-Chapman; Barbara J Stoll; Seetha Shankaran; Michele C Walsh; Kathy J Auten; Nancy A Miller; Pablo J Sánchez; Rosemary D Higgins; C Michael Cotten; P Brian Smith; Daniel K Benjamin
Journal:  Clin Infect Dis       Date:  2011-12-05       Impact factor: 9.079

2.  Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.

Authors:  Thomas J Walsh; Timothy Driscoll; Peter A Milligan; Nolan D Wood; Haran Schlamm; Andreas H Groll; Hasan Jafri; Antonio C Arrieta; Nigel J Klein; Irja Lutsar
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

3.  Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia.

Authors:  Nasrullah A Undre; Paul Stevenson; Antonio Freire; Antonio Arrieta
Journal:  Pediatr Infect Dis J       Date:  2012-06       Impact factor: 2.129

4.  Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children.

Authors:  Elizabeth H Doby; Daniel K Benjamin; Anne J Blaschke; Robert M Ward; Andrew T Pavia; Paul L Martin; Timothy A Driscoll; Michael Cohen-Wolkowiez; Cassandra Moran
Journal:  Pediatr Infect Dis J       Date:  2012-06       Impact factor: 2.129

5.  In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.

Authors:  D Andes; D J Diekema; M A Pfaller; J Bohrmuller; K Marchillo; A Lepak
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

6.  Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model.

Authors:  D Andes; T Stamsted; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

7.  The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants.

Authors:  Gloria P Heresi; Dale R Gerstmann; Michael D Reed; John N van den Anker; Jeffrey L Blumer; Laura Kovanda; James J Keirns; Donald N Buell; Gregory L Kearns
Journal:  Pediatr Infect Dis J       Date:  2006-12       Impact factor: 2.129

8.  Safety and pharmacokinetics of repeat-dose micafungin in young infants.

Authors:  D K Benjamin; P B Smith; A Arrieta; L Castro; P J Sánchez; D Kaufman; L J Arnold; L L Kovanda; T Sawamoto; D N Buell; W W Hope; T J Walsh
Journal:  Clin Pharmacol Ther       Date:  2009-11-04       Impact factor: 6.875

9.  The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates.

Authors:  William W Hope; Diana Mickiene; Vidmantas Petraitis; Ruta Petraitiene; Amy M Kelaher; Joanna E Hughes; Margaret P Cotton; John Bacher; James J Keirns; Donald Buell; Gloria Heresi; Daniel K Benjamin; Andreas H Groll; George L Drusano; Thomas J Walsh
Journal:  J Infect Dis       Date:  2008-01-01       Impact factor: 5.226

10.  Pharmacokinetics of an elevated dosage of micafungin in premature neonates.

Authors:  P Brian Smith; Thomas J Walsh; William Hope; Antonio Arrieta; Akitsugu Takada; Laura L Kovanda; Gregory L Kearns; David Kaufman; Taiji Sawamoto; Donald N Buell; Daniel K Benjamin
Journal:  Pediatr Infect Dis J       Date:  2009-05       Impact factor: 2.129
View more
  3 in total

Review 1.  Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.

Authors:  Jessica K Roberts; Chris Stockmann; Jonathan E Constance; Justin Stiers; Michael G Spigarelli; Robert M Ward; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

Review 2.  Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.

Authors:  Chris Stockmann; Jonathan E Constance; Jessica K Roberts; Jared Olson; Elizabeth H Doby; Krow Ampofo; Justin Stiers; Michael G Spigarelli; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 6.447

3.  Exposure-Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials.

Authors:  Laura L Kovanda; Thomas J Walsh; Daniel K Benjamin; Antonio Arrieta; David A Kaufman; P Brian Smith; Paolo Manzoni; Amit V Desai; Atsunori Kaibara; Peter L Bonate; William W Hope
Journal:  Pediatr Infect Dis J       Date:  2018-06       Impact factor: 2.129
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.